Journal of Pharmacological Sciences
Online ISSN : 1347-8648
Print ISSN : 1347-8613
Full Paper
Antidiabetic Effects of SGLT2-Selective Inhibitor Ipragliflozin in Streptozotocin–Nicotinamide-Induced Mildly Diabetic Mice
Atsuo TaharaEiji KurosakiMasanori YokonoDaisuke YamajukuRumi KiharaYuka HayashizakiToshiyuki TakasuMasakazu ImamuraLi QunHiroshi TomiyamaYoshinori KobayashiAtsushi NodaMasao SasamataMasayuki Shibasaki
Author information
JOURNALS FREE ACCESS

2012 Volume 120 Issue 1 Pages 36-44

Details
Abstract

Sodium-glucose cotransporter (SGLT) 2 plays an important role in renal glucose reabsorption, and inhibition of renal SGLT2 activity represents an innovative strategy for the treatment of hyperglycemia in diabetic patients. The present study investigated the antidiabetic effects of ipragliflozin, a SGLT2-selective inhibitor, in streptozotocin–nicotinamide-induced mildly diabetic mice, which exhibited a mild decline in glucose tolerance associated with the loss of early-phase insulin secretion. Oral administration of ipragliflozin increased urinary glucose excretion in a dose-dependent manner, an effect which was significant at doses of 0.3 mg/kg or higher and lasted over 12 h. In addition, ipragliflozin dose-dependently improved hyperglycemia and glucose intolerance with concomitant decreases in plasma insulin levels without causing hypoglycemia. Once-daily dosing of ipragliflozin (0.1 – 3 mg/kg) for 4 weeks attenuated hyperglycemia, glucose intolerance, and impaired insulin secretion. These results suggest that the SGLT2-selective inhibitor ipragliflozin increases urinary glucose excretion by inhibiting renal glucose reabsorption, improves hyperglycemia in streptozotocin–nicotinamide-induced mildly diabetic mice, and may be useful for treating type 2 diabetes.

Information related to the author
© 2012 The Japanese Pharmacological Society
Previous article Next article
feedback
Top